Skip to content

CAPTURE: Improving pain assessment for cancer patients, a cluster randomised control pilot trial

Cancer Pain-assessment toolkit for use in routine oncology outpatient services: Multi-centre cluster randomised pilot trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN86926298
Enrollment
180
Registered
2023-09-01
Start date
2023-10-30
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain in cancer patients Cancer

Interventions

Study design We will use a multi-centre cluster randomised pilot trial, with a nested qualitative sub-study. We will recruit twelve outpatient services across three tertiary oncology referral centres

Sponsors

University of Leeds
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients: 1. Attending a participating outpatient service during the trial period and, 2. Aged 18 years or over; 3. Have a diagnosis of cancer; 4. Self-report a score of > = 3 on the 0-10 Numerical Rating Scale (NRS) for worst pain in the past 72 hours; Healthcare professionals: 1. Work at a participating outpatient service during the study period.

Exclusion criteria

Exclusion criteria: Patients: 1. Clinical judgement will be used to determine patients that are too ill to take part, including those with severe mental health problems; 2. Considered by their clinical teams to be actively dying; 3. Unable to complete a NRS in English; 4. Are not expected to be available for first follow-up data collection (1-week). Healthcare professionals: 1. Do not have any contact with oncology outpatient patients.

Design outcomes

Primary

MeasureTime frame
1. Pain measured using the Brief Pain Inventory (BPI) at screening, baseline, 1 week, 1 month, 2 months 2. EQ-5D-5L measure of general health related quality of life at baseline, 1 week, 1 month, 2 months 3. Anxiety: Generalised Anxiety Disorder 7-item Scale (GAD-7) at baseline, 1 month, 2 months 4. Depression: Patient Health Questionnaire (PHQ-8) measure of depression at baseline, 1 month, 2 months 5. Symptoms: Edmonton Symptom Assessment System (EASA) at baseline, 1 month, 2 months

Secondary

MeasureTime frame
1. Basic demographics: age, ethnicity, marital status, sex, highest achieved education level by patient report at baseline 2. Recent medical history, cancer type and stage by patient report at baseline 3. Medications and referral check plus healthcare resource use, analgesic prescriptions, specialist service referral, healthcare resource use measured using patient records at baseline, 1 month, 2 months 4. Site level usual care offered and accessed by participant interview at 2 months

Countries

England, United Kingdom

Contacts

Public ContactOlivia Robinson
o.c.robinson@leeds.ac.uk+44 7984310078

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026